New Patent Battleground: Inter Partes Reviews Besiege Innovators

Inter partes review, a new patent challenge proceeding, is increasingly being deployed against biopharma companies by generic manufacturers, biosimilar sponsors and hedge fund manager Kyle Bass. What the industry is doing to fight back.